trovafloxacin has been researched along with sulbactam in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Andriole, VT; Dembry, LM; Farrel, PA; Gerrity, LA; Orcutt, DR | 1 |
| Falagas, ME; McDermott, L; Snydman, DR | 1 |
| Dudley, MN; Gilbert, D; Zinner, SH | 1 |
| Canawati, HN; Montgomerie, JZ; Schick, DG | 1 |
| Aeschlimann, JR; Hershberger, E; Moldovan, T; Rybak, MJ | 1 |
| Aeschlimann, JR; Hershberger, E; Rybak, MJ | 1 |
| Calvo, A; García, R; Gómez-Lus, ML; Leturia, A; Sevillano, D; Valero, E | 1 |
9 other study(ies) available for trovafloxacin and sulbactam
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest.
Topics: Ampicillin; Anti-Infective Agents; Bacteria, Aerobic; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Fluoroquinolones; Gentamicins; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Sulbactam; Vancomycin | 1997 |
Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group.
Topics: Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bacteroides fragilis; Ciprofloxacin; Clindamycin; Drug Therapy, Combination; Fluoroquinolones; Hydrogen-Ion Concentration; Imipenem; Meropenem; Microbial Sensitivity Tests; Naphthyridines; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Thienamycins | 1997 |
Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection.
Topics: Ampicillin; Anti-Infective Agents; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enterococcus faecalis; Enterococcus faecium; Fluoroquinolones; Gram-Positive Bacterial Infections; Microbial Sensitivity Tests; Naphthyridines; Sulbactam | 1998 |
In vitro activity of the combination of trovafloxacin and other antibiotics against enterococci.
Topics: Ampicillin; Ampicillin Resistance; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enterococcus; Enterococcus faecalis; Fluoroquinolones; Gentamicins; Humans; Microbial Sensitivity Tests; Naphthyridines; Novobiocin; Rifampin; Sulbactam; Teicoplanin; Vancomycin | 1997 |
Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by
Topics: Ampicillin; Anti-Bacterial Agents; Antibiotics, Antitubercular; Drug Therapy, Combination; Fluoroquinolones; Gentamicins; Glycopeptides; Lipoglycopeptides; Microbial Sensitivity Tests; Naphthyridines; Rifampin; Staphylococcus aureus; Sulbactam; Teicoplanin; Time Factors; Vancomycin; Virginiamycin | 1999 |
Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
Topics: Ampicillin; Anti-Infective Agents; Drug Therapy, Combination; Fluoroquinolones; Methicillin Resistance; Microbial Sensitivity Tests; Naphthyridines; Staphylococcus aureus; Sulbactam; Vancomycin Resistance | 2000 |
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
Topics: Acinetobacter; Acinetobacter Infections; Ampicillin; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Opportunistic Infections; Quinolines; Sulbactam; Thienamycins | 2001 |